UNSPSC 51383311: Diclofenac diethylamine

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C14H11CL2NO2.C4H11N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6TGQ35Z71K. European Medicines Agency schedules diclofenac diethylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01669MIG. The term diclofenac diethylamine is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule diclofenac diethylamine under HS 29224995 and SITC 51465.

As of Q4 2014, DICLOFENAC DIETHYLAMINE remains US FDA's Preferred Term for this commodity. Diclofenac diethylamine bears US NLM identifiers UMLS ID C0771369 and NCI Concept Code C87322. SMILES: CCNCC.C1CCC(C(C1)CC(=O)O)NC2C(CCCC2CL)CL.

UNSPSC 51383311 Diclofenac diethylamine is a Commodity code that in recent state and local procurement activity covers pharmaceutical procurement more broadly — including naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through state and local health systems, cooperative purchasing alliances, and community health initiatives. State and local issuing bodies soliciting under or near this code span county health departments, state health and human services agencies, and multistate cooperative purchasing organizations. The actual work being bought involves competitive bidding for pharmaceutical inventory, pricing schedules tied to authorized wholesalers, compliance with FDA and drug-supply-chain security standards, and fulfillment through fixed-fee or net-price contracting models with quarterly or ongoing deliveries to designated facilities.

Recent activity includes Seminole County, Florida's IFB (IFB60459723LAS, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building; the Texas Health and Human Services Commission's Request for Information (HHS0017013, posted April 3, 2026) on direct-to-manufacturer prescription programs exploring vendor capabilities for pharmacy benefit management outside traditional PBM and wholesaler channels; and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) RFP (S1070000015802, proposals due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Geographic activity centers on Florida, Texas, and Minnesota; vendors pursuing this code should expect administrative fee structures (3 percent in the MMCAP example), insurance requirements including commercial general liability coverage, cGMP and DSCSA compliance, and contract terms ranging from two to three years with optional renewals.